Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound 068
- Development stage
- Preclinical
- Modality
- Small Molecules
01
Overview
Compound 068 is a synthetic chalcone-based small molecule inhibitor developed for the treatment of ovarian cancer. Identified through computational 3D-QSAR (Quantitative Structure-Activity Relationship) modeling and subsequently validated in experimental assays, the compound demonstrates potent antiproliferative activity against the A2780 ovarian cancer cell line. Its mechanism of action involves the induction of intracellular reactive oxygen species (ROS), which triggers apoptotic pathways in malignant cells. Compound 068 is specifically designed to address the challenges of late-stage diagnosis and chemoresistance in gynecological malignancies, representing a promising scaffold for the development of targeted antineoplastic therapies.
Beyond the preview
Go deeper on Compound 068.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Compound 068.